文献速递胃肠动力与功能性疾病

并非所有FODMAP都相同:肠易激综合征患者随机再引入试验结果

All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-05-09

本研究纳入符合Rome IV标准的肠易激综合征患者,经2至4周开放标签FODMAP限制后症状改善者进入10周盲法再引入阶段,每种FODMAP再引入7天。45例入组,25例限制后改善,21例继续再引入。果聚糖和半乳寡糖分别与腹痛加重相关(P=.007和P=.04),半乳寡糖与腹胀增加相关(P=.03);腹胀和腹痛在研究期间无论是否再引入FODMAP均加重(P=.006)。作者认为再引入特定FODMAP可能导致症状产生,并为未来比较限制性低FODMAP饮食与标准低FODMAP饮食的试验提供依据。

要点

  • 果聚糖和半乳寡糖再引入分别与腹痛加重相关(P=.007和P=.04)。
  • 半乳寡糖再引入与腹胀增加相关(P=.03)。
  • 腹胀和腹痛在研究期间无论是否再引入FODMAP均加重(P=.006)。

核心结论

  • 再引入特定FODMAP可能导致对低FODMAP饮食有反应的肠易激综合征患者产生症状。
  • 结果为未来比较限制性低FODMAP饮食与标准低FODMAP饮食的治疗效果试验提供了有力依据。

研究设计与样本

  • 符合Rome IV标准的肠易激综合征患者受邀参加为期12周的研究以识别个体FODMAP敏感性。
  • 在2至4周开放标签FODMAP消除期后症状改善的受试者进入为期10周的盲法再引入阶段,每种FODMAP再引入7天。
  • 研究期间每日记录症状严重程度(0-10分数字评定量表),采用混合效应统计模型分析。
  • 2018年至2020年间共入组45例受试者,25例在FODMAP消除后改善,21例继续进入再引入阶段。

主要发现

  • 果聚糖与腹痛加重相关(P=.007)。
  • 半乳寡糖与腹痛加重相关(P=.04)。
  • 半乳寡糖与腹胀增加相关(P=.03)。
  • 腹胀和腹痛在研究期间无论是否再引入FODMAP均加重(P=.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A diet low in fermentable oligo, di, monosaccharides, and polyols (FODMAPs) is one of the recommended management strategies for irritable bowel syndrome (IBS). However, while effective, adherence to restricting dietary FODMAPs can be challenging and burdensome. The question remains whether limiting all FODMAPs during the restrictive phase of the diet is necessary for symptomatic improvement in the dietary treatment of IBS, or if targeting selected groups of FODMAPs for restriction is sufficient for clinical response. Our study aimed to determine which individual FODMAPs are most likely to lead to symptom generation in patients with IBS who have improved with fodmap restriction. METHODS: Patients meeting Rome IV criteria for IBS were invited to participate in a 12-week study to identify individual FODMAP sensitivities. Those subjects who demonstrated symptom improvement after a 2- to 4-week open-label FODMAP elimination period were recruited to a 10-week blinded-phased FODMAP reintroduction phase of 7 days for each FODMAP. Throughout the study period, daily symptom severity (0-10 point numerical rating system) was recorded. A mixed effect statistical analysis model was used. RESULTS: Between 2018 and 2020, 45 subjects were enrolled. Twenty-five subjects improved with FODMAP elimination, and 21 patients continued into the reintroduction phase of the study. Fructans and galacto-oligosaccharides (GOS) both were associated with worsened abdominal pain (P = .007 and P = .04, respectively). GOS were associated with an increase in bloating (P = 03). Both bloating and abdominal pain worsened throughout the study, regardless of the FODMAP reintroduction (P = .006). CONCLUSION: Our results suggest that the reintroduction of select FODMAPs may be responsible for symptom generation in patients with IBS who have responded to a low FODMAP diet, and provide a strong rationale for performing a future trial comparing the treatment effects of a limited low-FODMAP diet and a standard low-FODMAP diet. CLINICALTRIALS: GOV: NCT03052439.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Eswaran S, Jencks KJ, Singh P, et al. All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2024. PMID: 38729390. doi:10.1016/j.cgh.2024.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。